Shortages of Oral Progesterone Affect Menopause Treatment Access

The U.S. is facing intermittent shortages of oral progesterone, which is critical for hormone replacement therapy. This shortage is attributed to a surge in demand following the FDA's removal of a safety warning, impacting many patients relying on these treatments. The situation raises concerns about access to essential medications for menopause management.